ASLAN PHARMACEUTICALS LIMITED: ASLAN Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Data readout for TREK-AD Phase 2b study of eblasakimab on track for early July 2023Four abstracts on eblasakimab and farudodstat, including two late-breakers, to be presented at the 1st International Societies

Related Keywords

Tokyo ,Japan ,Singapore ,California ,United States ,Russia ,Ukraine ,American ,Carl Firth ,Ashleyr Robinson ,Emma Thompson ,Brett King ,Alan Bianchi ,Pharmaceuticals Nasdaq ,Exchange Commission ,Commission File No ,Company Us Securities ,Linkedin ,International Societies For Investigative Dermatology ,Spurwing Communications ,International Societies Of Investigative Dermatology ,Development Day ,Company Annual Report On Form ,Thermo Fisher ,Exchange Commission On ,Lifesci Advisors ,Stockholders Of The Company ,Thermo Fisher Scientific Inc ,Yale University School Of Medicine ,International Societies ,Investigative Dermatology ,Atopic Dermatitis ,Purchase Agreement ,American Depositary Share ,Key Opinion Leader ,Associate Professor ,Yale University School ,Investor Relations ,Commercial Lead Advisor ,Executive Director ,Nasdaq Capital Market ,San Mateo ,Commission File ,Annual Report ,Sci Advisors ,Caslan ,Pharmaceuticals ,Imited ,Reports ,First ,Quarter ,023 ,Financial ,Results ,Rovides ,Corporate ,Update ,